Acadian Asset Management’s Denali Therapeutics DNLI Stock Holding History

Acadian Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$166K	Buy	+6,476	New	+$133K	﹤0.01%	1668
2024 Q4	–	Sell	-2,749	Closed	-$80K	–	1758
2024 Q3	$80K	Buy	+2,749	New	+$68.1K	﹤0.01%	1667
2022 Q1	–	Sell	-11,805	Closed	-$526K	–	1670
2021 Q4	$526K	Buy	11,805 +957	+9%	+$45.3K	﹤0.01%	995
2021 Q3	$547K	Sell	10,848 -15,906	-59%	-$896K	﹤0.01%	1014
2021 Q2	$2.1M	Buy	26,754 +20,817	+351%	+$1.29M	0.01%	698
2021 Q1	$339K	Buy	+5,937	New	+$397K	﹤0.01%	1326
2019 Q3	–	Sell	-11,650	Closed	-$241K	–	1902
2019 Q2	$241K	Buy	11,650 +6,728	+137%	+$151K	﹤0.01%	1181
2019 Q1	$114K	Buy	+4,922	New	+$103K	﹤0.01%	1481

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management's DNLI Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 6,476 shares worth $166K. The stake represents ﹤0.01% of the portfolio and ranks #1668 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in DNLI as recently as Q3 2024.

Acadian Asset Management first reported a position in DNLI in Q1 2019 and has held it in 8 quarters since. The position peaked at $2.1M in Q2 2021. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Acadian Asset Management held 6,476 shares of Denali Therapeutics worth $166K as of Q2 2026.
Denali Therapeutics was a new Acadian Asset Management position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1668 holding.
Acadian Asset Management first reported a position in Denali Therapeutics in Q1 2019 and has held it in 8 quarters since.
Acadian Asset Management's Denali Therapeutics position peaked at $2.1M in Q2 2021.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.